However, checkpoint inhibitors currently used to target CD8+ T cells (e.g., anti-CTLA-4 and/or anti-PD-1 mAbs) have not been shown to be efficient for all tumor types and may cause a partial remission in the majority of tumors. This evidence concerns the gene CTLA4 and neoplasm.